Early Clinical Trial

The PI of this project was:

This project was funded by: Janssen Pharmaceutical

The term of this project was: April 2018 to September 2023

The number of subjects scanned during this project was: 30

The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer’s dementia.